山东医药
山東醫藥
산동의약
SHANDONG MEDICAL JOURNAL
2014年
15期
11-13
,共3页
原发性肝癌%巴塞罗那临床肝癌分期%化疗栓塞术%总生存率
原髮性肝癌%巴塞囉那臨床肝癌分期%化療栓塞術%總生存率
원발성간암%파새라나림상간암분기%화료전새술%총생존솔
primary hepatocellular carcinoma%Barcelona Clinic Liver Cancer classification%chemoembolization%o-verall survival
目的：探讨肿瘤切除术前行经皮股动脉穿刺肝动脉化疗栓塞术（TACE）对巴塞罗那临床肝癌（BCLC）分期B期患者预后的影响。方法对309例首次行肝癌切除术的BCLC分期B期患者的临床资料进行回顾性分析，根据术前是否行TACE分为联合组和手术组，用两独立样本t检验和Pearson χ2检验比较两组一般临床资料，用Log-rank检验和Cox比例风险回归模型比较两组生存率。结果两组一般临床资料无统计学差异（ P＞0．05）；联合组和手术组中位生存期分别为36、26个月，组间比较P＜0．05（χ2＝9．226）；治疗方式、肿瘤直径、手术切缘和血清AFP水平是影响患者生存率的危险因素（P＜0．05），且治疗方式是影响患者预后的独立危险因素（RR为1．576，95％CI为1．157～2．146， P＝0．004）。结论对于BCLC分期B期患者，在切除术前给予辅助性TACE治疗有望延长术后生存时间。
目的：探討腫瘤切除術前行經皮股動脈穿刺肝動脈化療栓塞術（TACE）對巴塞囉那臨床肝癌（BCLC）分期B期患者預後的影響。方法對309例首次行肝癌切除術的BCLC分期B期患者的臨床資料進行迴顧性分析，根據術前是否行TACE分為聯閤組和手術組，用兩獨立樣本t檢驗和Pearson χ2檢驗比較兩組一般臨床資料，用Log-rank檢驗和Cox比例風險迴歸模型比較兩組生存率。結果兩組一般臨床資料無統計學差異（ P＞0．05）；聯閤組和手術組中位生存期分彆為36、26箇月，組間比較P＜0．05（χ2＝9．226）；治療方式、腫瘤直徑、手術切緣和血清AFP水平是影響患者生存率的危險因素（P＜0．05），且治療方式是影響患者預後的獨立危險因素（RR為1．576，95％CI為1．157～2．146， P＝0．004）。結論對于BCLC分期B期患者，在切除術前給予輔助性TACE治療有望延長術後生存時間。
목적：탐토종류절제술전행경피고동맥천자간동맥화료전새술（TACE）대파새라나림상간암（BCLC）분기B기환자예후적영향。방법대309례수차행간암절제술적BCLC분기B기환자적림상자료진행회고성분석，근거술전시부행TACE분위연합조화수술조，용량독립양본t검험화Pearson χ2검험비교량조일반림상자료，용Log-rank검험화Cox비례풍험회귀모형비교량조생존솔。결과량조일반림상자료무통계학차이（ P＞0．05）；연합조화수술조중위생존기분별위36、26개월，조간비교P＜0．05（χ2＝9．226）；치료방식、종류직경、수술절연화혈청AFP수평시영향환자생존솔적위험인소（P＜0．05），차치료방식시영향환자예후적독립위험인소（RR위1．576，95％CI위1．157～2．146， P＝0．004）。결론대우BCLC분기B기환자，재절제술전급여보조성TACE치료유망연장술후생존시간。
Objective To investigate the effect of preoperative transarterial chemoembolization ( TACE) on the prog-nosis of stage B hepatocellular carcinoma (HCC) in the Barcelona Clinic Liver Cancer (BCLC) classification.Methods A total of 309 stage B hepatocellular carcinoma patients treated with hepatectomy were enrolled in our retrospective analy -sis, among whom, 136 patients underwent preoperative TACE and hepatectomy (TACE group) and 173 patients had only hepatectomy (non-TACE group).Independent-Samples t-test and Pearson χ2 test were used to analyze the clinical data of the two groups.Long-rank test and Cox regression models were used to compare the overall survival rates .Results There were no significant differences in clinical data between the two groups (P>0.05).The median survival time was 36 and 26 months for the TACE group and non-TACE group, respectively (χ2 =9.226, P<0.05).In the Long-rank univariate anal-ysis, different treatments, diameter of tumor, surgical margin status and the level of serum AFP were risk factors in influen-cing the survival HCC patients (P<0.05).Cox multivariate analysis showed that different treatment was an independent factor in affecting the prognosis of HCC patients (RR:1.576, 95%CI:1.157-2.146, P=0.004).Conclusion Pre-operative adjuvant TACE therapy may prolong the survival time in BCLC stage B HCC patients treated with hepatectomy .
